Abstract 182P
Background
Combining LEN with anti-PD-1 antibodies (LEN+PD1) has shown promising anti-tumour effect against advanced HCC in KEYNOTE 524 and Study 117. We assessed LEN+PD1 vs LEN monotherapy in Chinese patients (Pts) with advanced HCC.
Methods
This real-world study included Pts with untreated advanced HCC who received lenvatinib (8 mg/d regardless of bodyweight) ± anti-PD-1 antibodies (q3wk) between Nov 2018 and Nov 2019, and had ≥1 efficacy and safety assessment. Endpoints included objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) evaluated using mRECIST and RECIST 1.1 every 2 months from treatment initiation, ALBI score and safety.
Results
The study included 22 patients who received LEN+PD1 and 22 who received LEN. For patients in the LEN+PD1 and LEN groups, median follow-up was 6.6 and 5.3 months, mean age was 54.8 and 53.2 years, 81.8 and 90.9% had BCLC stage C disease, and 72.7 and 68.1% were Child-Pugh A, respectively. ORR and DCR were numerically higher in the LEN+PD1 group vs the LEN group (Table) and median PFS was 12.1 (95% CI: 7.9, 16.2) vs 8.9 months (95% CI: 6.6, 11.2; HR=0.58; 95% CI: 0.17, 1.93), respectively. A similar proportion of patients in both groups decreased one ALBI level from baseline (p=0.9331). The most common AEs in the LEN+PD1 group were hypertension (22.7% [5]), decreased appetite (18.2% [4]) and ALT increase (13.6% [3]) and in the LEN group were ALT increase (31.8% [7]), proteinuria (18.2% [4]) and decreased appetite (18.2% [4]). No unexpected safety signals were observed. Table: 182P
n (%) | RECIST 1.1 | mRECIST | ||||
LEN + PD1 n=22 | LEN n =22 | p | LEN + PD1 n=22 | LEN n =22 | p | |
ORR | 10 (45.5) | 4 (18.2) | 0.052 | 11 (50.0) | 7 (31.8) | 0.220 |
DCR | 20 (90.9) | 17 (77.3) | 0.216 | 20 (90.9) | 17 (77.3) | 0.216 |
Complete response | 1 (4.5) | 0 | 0.204 | 3 (13.6) | 2 (9.1) | 0.526 |
Partial response | 9 (40.9) | 4 (18.2) | 8 (36.4) | 5 (22.7) | ||
Stable disease | 10 (45.5) | 13 (59.1) | 9 (40.9) | 10 (45.5) | ||
Progressive disease | 2 (9.1) | 5 (22.7) | 2 (9.1) | 5 (22.7) |
Conclusions
LEN ± anti-PD-1 antibodies was effective and well tolerated in first-line treatment of patients with advanced HCC. LEN+PD1 showed a trend towards higher ORR, DCR, and longer PFS vs LEN, with no increase in hepatotoxicity. However, further evaluation in randomized, prospective trials is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session